InterCure Ltd.

INCR

IL0011063760

Healthcare Facilities & Services

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 15:24:52 14/07/2025 BST			5-day change	1st Jan Change
509.90 ^ILa	-0.08%		+0.37%	-14.13%

05-01	InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
02-12	Intercure Names Announces Board Changes, Effective February 13, 2025	CI

InterCure Ltd.(TASE:INCR) dropped from S&P Global BMI Index

Published on 18/09/2023 at 05:00

Latest news about InterCure Ltd.

InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	05-01	CI
Intercure Names Announces Board Changes, Effective February 13, 2025	02-12	CI
InterCure Ltd. announced that it has received ILS 35.499998 million in funding	12-18	CI
InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	29/08/24	CI
InterCure Partners with Cookies to Launch Branded Products in Germany	28/08/24	MT
InterCure Announces Expansion of its Strategic Partnership with Cookies to Germany	28/08/24	CI
InterCure Ltd. Provides Revenue Guidance for the Full Year 2024	01/05/24	CI
InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	01/05/24	CI
InterCure Ltd. Provides Earnings Guidance for the Second Half and Full Year of 2023	01/04/24	CI
InterCure Ltd. Expects to Launch Its First Products in Germany in the Coming Months	22/03/24	CI
InterCure Ltd. Announces Resignation of Rami Levy as Chief of Operations	13/02/24	CI
InterCure Ltd. entered into a share purchase agreement to acquire Leon Pharm Ltd for ILS 8.3 million.	30/01/24	CI
InterCure Ltd.(TASE:INCR) dropped from S&P Global BMI Index	18/09/23	CI
InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	01/09/23	CI
Intercure to Delist Its Shares From the Toronto Stock Exchange	10/07/23	MT
InterCure Provides Update About Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger	12/06/23	MT
InterCure Ltd., 2022 Earnings Call, Apr 04, 2023	04/04/23
InterCure Ltd. entered into an agreement to acquire 51% stake in Orni Pharmacy Ltd.	15/11/22	CI
InterCure to Launch Trading on Nasdaq Wednesday	01/09/21	MT
InterCure Ltd. Announces Earnings Results for the Second Quarter Ended June 30, 2021	16/08/21	CI
InterCure Provided Update on Its NASDAQ Listing	12/07/21	MT
InterCure Ltd signed a Letter of Intent to acquire Cann Pharmaceutical Ltd. for $35 million.	04/04/21	CI
InterCure : Israel's Canndoc signs cannabis import-export deal with Tilray	02/01/20	RE
Regenera Pharma Ltd. announced that it expects to receive funding from InterCure Ltd. and other investors	17/12/16	CI
InterCure Ltd. announced that it has received ILS 1.5 million in funding	03/12/16	CI

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

Employees

320

Sector

Healthcare Facilities & Services

Calendar

08-17 - Q2 2025 Earnings Release (Projected)

More about the company